NASDAQ:AAPG - Nasdaq - ADR - Currency: USD
NASDAQ:AAPG (5/27/2025, 8:00:00 PM)
25.815
-0.66 (-2.51%)
The current stock price of AAPG is 25.815 USD. In the past month the price increased by 2.08%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.08 | 328.06B | ||
AMGN | AMGEN INC | 13.46 | 150.26B | ||
GILD | GILEAD SCIENCES INC | 14.09 | 135.70B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.53B | ||
REGN | REGENERON PHARMACEUTICALS | 13.61 | 65.13B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.83B | ||
ARGX | ARGENX SE - ADR | 98.77 | 35.40B | ||
ONC | BEIGENE LTD-ADR | 6.1 | 25.76B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.69B | ||
NTRA | NATERA INC | N/A | 21.46B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.04B | ||
BIIB | BIOGEN INC | 8.12 | 18.81B |
Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. The company is headquartered in Suzhou, Jiangsu and currently employs 567 full-time employees. The company went IPO on 2019-10-28. The Company’s main business is engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus and certain age-related diseases. The Company’s main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918 and other products. The Company’s products are mainly used to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. The firm mainly conducts its business in the domestic market.
ASCENTAGE PHARMA GR-ADR
68 Xinqing Road, Suzhou Industrial Park
Suzhou JIANGSU CN
Employees: 567
The current stock price of AAPG is 25.815 USD. The price decreased by -2.51% in the last trading session.
The exchange symbol of ASCENTAGE PHARMA GR-ADR is AAPG and it is listed on the Nasdaq exchange.
AAPG stock is listed on the Nasdaq exchange.
14 analysts have analysed AAPG and the average price target is 26.43 USD. This implies a price increase of 2.4% is expected in the next year compared to the current price of 25.815. Check the ASCENTAGE PHARMA GR-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ASCENTAGE PHARMA GR-ADR (AAPG) has a market capitalization of 2.25B USD. This makes AAPG a Mid Cap stock.
ASCENTAGE PHARMA GR-ADR (AAPG) currently has 567 employees.
ASCENTAGE PHARMA GR-ADR (AAPG) has a support level at 24.53 and a resistance level at 26.48. Check the full technical report for a detailed analysis of AAPG support and resistance levels.
The Revenue of ASCENTAGE PHARMA GR-ADR (AAPG) is expected to decline by -48.7% in the next year. Check the estimates tab for more information on the AAPG EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AAPG does not pay a dividend.
ASCENTAGE PHARMA GR-ADR (AAPG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.63).
The outstanding short interest for ASCENTAGE PHARMA GR-ADR (AAPG) is 0.03% of its float. Check the ownership tab for more information on the AAPG short interest.
ChartMill assigns a technical rating of 6 / 10 to AAPG.
ChartMill assigns a fundamental rating of 3 / 10 to AAPG. Both the profitability and financial health of AAPG have multiple concerns.
Over the last trailing twelve months AAPG reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS increased by 61.43% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -15.49% | ||
ROE | -153.46% | ||
Debt/Equity | 4.46 |
ChartMill assigns a Buy % Consensus number of 87% to AAPG. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -182.73% and a revenue growth -48.7% for AAPG